Form 4: VOR Biopharma 10% Owner Sells 984,805 Shares

A 10% owner and director of Vor Biopharma Inc. reported multiple sales of common stock totaling 984,805 shares in mid-September 2025.

Summary

• Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma Inc. (VOR), reported the sale of 984,805 shares of common stock across three transactions.
• On September 11, 2025, 284,805 shares were sold at a weighted average price of $1.8308 per share.
• On September 12, 2025, an additional 300,000 shares were sold at a weighted average price of $1.7541 per share.
• On September 15, 2025, 400,000 shares were sold at a weighted average price of $1.6408 per share.
• Following these transactions, Reprogrammed Interchange LLC beneficially owns 33,228,487 shares of Vor Biopharma common stock.
• Reid Hoffman, also a director and 10% owner, may be deemed a beneficial owner of these securities due to his shared control and indirect pecuniary interest in Reprogrammed Interchange LLC, though he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 3

Explanation: The sentiment is negative due to substantial insider selling by a major shareholder and director, which often signals a lack of confidence or a belief that the stock is overvalued.

Negatives

• Significant insider selling by a 10% owner and director, Reprogrammed Interchange LLC, totaling nearly one million shares.
• The sales occurred at progressively lower weighted average prices, from $1.8308 to $1.6408, which could indicate a lack of confidence or a need for liquidity.

Risks

• Insider selling by a major shareholder and director can be interpreted as a negative signal regarding the company's future prospects or current valuation.
• The substantial volume of shares sold could put downward pressure on the stock price.
• Potential for market participants to view these sales as a lack of conviction from a key stakeholder.

Future Outlook

No explicit forward-looking statements or guidance were provided in this filing.

Management Comments

• Reid Hoffman disclaims beneficial ownership of the securities held by Reprogrammed Interchange LLC, except to the extent of his pecuniary interest therein.

Industry Context

Insider selling, particularly by a significant owner and director, can be viewed negatively across all industries, as it may signal a lack of confidence in the company's future performance or valuation. In the biotech sector, where company value is often tied to future pipeline success, such sales can be particularly scrutinized.

Related Party Transactions

• The reported sales of common stock by Reprogrammed Interchange LLC are considered related party transactions, as the entity is a 10% owner and director of Vor Biopharma Inc.

Stakeholder Impact

• Shareholders may perceive the significant insider selling as a negative indicator, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Employees and other stakeholders might interpret these sales as a signal of internal concerns about the company's future.

Key Dates

Recommendation

The significant insider selling by a 10% owner and director, Reprogrammed Interchange LLC, disposing of nearly one million shares at declining prices, is a strong negative signal. Such actions by a key stakeholder often indicate a lack of confidence in the company's future performance or a belief that the stock is currently overvalued. This could lead to further downward pressure on the stock price, making a 'sell' recommendation appropriate for seasoned investors.

Keywords

Vor Biopharma, VOR, SEC Form 4, Insider Selling, Stock Sale, Reprogrammed Interchange LLC, Reid Hoffman, 10% Owner, Director, Common Stock